Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28378909 | 0.87 | MAP3K5 (0.52) | MAP3K5MAP3K6 | |
| SCHEMBL19258658 | 0.87 | MAP3K5 (0.64) | MAP3K5MAP3K6 | |
| SCHEMBL20802893 | 0.87 | MAP3K5 (0.53) | MAP3K5MAP3K6 | |
| SCHEMBL28383614 | 0.84 | MAP3K5 (0.49) | MAP3K5MAP3K6 | |
| SCHEMBL28656996 | 0.80 | MAP3K5 (0.53) | MAP3K5MAP3K6 | |
| SCHEMBL28643371 | 0.78 | GRM5 (0.52) | MAP3K5MAP3K6 | |
| SCHEMBL28649130 | 0.78 | GRM5 (0.45) | MAP3K5 | |
| SCHEMBL22474011 | 0.77 | MAP3K5 (0.51) | MAP3K5MAP3K6 | |
| SCHEMBL25624297 | 0.76 | MAP3K5 (0.52) | MAP3K5MAP3K6 | |
| SCHEMBL18027903 | 0.76 | MAP3K5 (0.65) | MAP3K5MAP3K6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138969-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-21 | — | — | US | disclosed |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-15 | — | — | US | disclosed |
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| WO-2019051265-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | DAPK1, ATF1, BAD | MAP3K5 22/4885MAP3K6 11/4885 |
| US-20260138969-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | CASP1, CASP3, BAD | MAP3K5 277/4885MAP3K6 142/4885 |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | DAPK1, ATF1, BAD | MAP3K5 22/4885MAP3K6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.